Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory studyFrancesco Schettini, Daniele Generali, Alessandra Fontana et al.|European Journal of Cancer|2023Cited by 23
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity TrialFrancesco Schettini, Daniele Generali, Alfredo Molteni et al.|Frontiers in Oncology|2021Cited by 19
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of LiteratureOttavia Bernocchi, Daniele Generali, Marianna Sirico et al.|Pharmaceuticals|2021Cited by 12
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast CancerMarianna Sirico, Daniele Generali, Ottavia Bernocchi et al.|Cancers|2020Cited by 9
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET studySilvia Paola Corona, Daniele Generali, Fabiola Giudici et al.|Oncotarget|2020Cited by 8